Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA; Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Department of Pathology, Mercy Medical Center, Baltimore, MD, USA.
Gynecol Oncol. 2014 Jun;133(3):473-9. doi: 10.1016/j.ygyno.2014.03.563. Epub 2014 Mar 25.
Recent studies have demonstrated that lymphovascular space invasion (LVSI) is associated with increased risk of hematogenous and lymphatic metastasis and poor clinical outcome of women with epithelial ovarian cancer. Given the suspected role of estrogen in promoting ovarian cancer metastasis, we examined potential links between estrogen receptor and LVSI in high-grade serous ovarian carcinoma.
Tumoral expression of ER, PR, p53, MDR1, EGFR, HER2, DNA ploidy, and S-phase fraction was examined for 121 cases of stage I-IV high-grade serous ovarian carcinoma samples obtained at primary cytoreductive surgery. Biomarker expression was correlated to LVSI and survival outcomes.
LVSI was observed in 101 (83.5%) of all cases. Immunohistochemistry of tested biomarkers showed ER (86.7%) to be the most commonly expressed followed by p53 (71.4%), HER2 (68.3%), EGFR (52.1%), MDR-1 (14.3%), and PR (8.9%). ER expression was positively correlated to PR expression (r=0.31, p=0.001). LVSI was only correlated with ER (odds ratio 6.27, 95%CI 1.93-20.4, p=0.002) but not with other biomarkers. In multivariate analysis, ER remained significantly associated with LVSI (p=0.039). LVSI remained a significant prognostic factor for decreased progression-free survival (HR 3.01, 95%CI 1.54-5.88, p=0.001) and overall survival (HR 2.69, 95%CI 1.18-6.23, p=0.021) while ER-expression did not remain as a significant variable in multivariate analysis.
Our data demonstrated that estrogen receptor was positively correlated with LVSI that was an independent prognostic indicator of poor survival outcomes of high-grade serous ovarian carcinoma. This study emphasizes the importance of estrogen pathway in promoting lymphatic or vascular spread of high-grade serous ovarian carcinoma.
最近的研究表明,淋巴血管空间侵犯(LVSI)与上皮性卵巢癌患者血行和淋巴转移的风险增加以及临床结局不良有关。鉴于雌激素在促进卵巢癌转移中的可疑作用,我们研究了高分级浆液性卵巢癌中雌激素受体与 LVSI 之间的潜在联系。
对 121 例初次细胞减灭术时获得的 I-IV 期高分级浆液性卵巢癌样本进行 ER、PR、p53、MDR1、EGFR、HER2、DNA 倍体和 S 期分数的肿瘤表达检测。生物标志物表达与 LVSI 和生存结果相关。
所有病例中 LVSI 为 101 例(83.5%)。经测试的生物标志物的免疫组化显示 ER(86.7%)是最常见的表达,其次是 p53(71.4%)、HER2(68.3%)、EGFR(52.1%)、MDR-1(14.3%)和 PR(8.9%)。ER 表达与 PR 表达呈正相关(r=0.31,p=0.001)。LVSI 仅与 ER 相关(优势比 6.27,95%CI 1.93-20.4,p=0.002),与其他生物标志物无关。多变量分析中,ER 与 LVSI 仍显著相关(p=0.039)。LVSI 仍是无进展生存期(HR 3.01,95%CI 1.54-5.88,p=0.001)和总生存期(HR 2.69,95%CI 1.18-6.23,p=0.021)显著降低的独立预后因素,而 ER 表达在多变量分析中不再是显著变量。
我们的数据表明,雌激素受体与 LVSI 呈正相关,LVSI 是高分级浆液性卵巢癌生存结局不良的独立预后指标。这项研究强调了雌激素通路在促进高级别浆液性卵巢癌淋巴管或血管扩散中的重要性。